Comparison of Metagenomic Sequencing and the NanoString nCounter Analysis System for the Characterization of Bacterial and Viral Communities in Vaginal Samples.
NanoString nCounter
microbiome
sequencing
vagina
virome
Journal
mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533
Informations de publication
Date de publication:
26 Oct 2022
26 Oct 2022
Historique:
pubmed:
25
8
2022
medline:
29
10
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
DNA sequencing assays have been used to characterize the vaginal microbiome and to identify associations with clinical outcomes. The purpose of this study was to evaluate the utility of the NanoString nCounter platform, a more efficient assay compared to sequencing, for the characterization of vaginal microbial communities. A panel of NanoString nCounter probes was designed to detect common vaginal bacteria and viruses with relevance to reproductive health. A defined synthetic community of microbes and 43 clinical samples were interrogated with NanoString nCounter assays and compared to known compositions or metagenomic shotgun sequencing (MSS) results. The NanoString nCounter platform and MSS were able to distinguish closely related microbes. In clinical samples, the relative abundance of bacterial species was similar between the two assays. The assays sometimes disagreed when targets were present at low abundance. More viruses were detected by MSS than by nCounter. However, the nCounter assays are able to provide results in about 30 h with minimal hands-on time, whereas MSS requires at least 138 to 178 h with extensive hands-on time. The reagent cost for the two assays was similar, but the overall cost of the nCounter was lower due to the minimal hands-on time. MSS can be used to inform the design of a targeted multiplex panel for the assessment of vaginal microbial communities, thereby allowing for more cost-effective and rapid screening of patient samples for research studies. The sensitivity for low abundance microbes could be improved, possibly by adding additional target amplification cycles before nCounter assessment. This approach has potential as an assay with both research and clinical applications.
Identifiants
pubmed: 36000741
doi: 10.1128/msphere.00197-22
pmc: PMC9599496
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0019722Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI159038
Pays : United States
Références
Chem Biodivers. 2012 May;9(5):965-76
pubmed: 22589096
Nat Med. 2019 Jun;25(6):1012-1021
pubmed: 31142849
Annu Rev Microbiol. 2012;66:371-89
pubmed: 22746335
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9966-9971
pubmed: 28847941
Front Cell Infect Microbiol. 2020 Aug 11;10:354
pubmed: 32850469
Nat Biotechnol. 2008 Mar;26(3):317-25
pubmed: 18278033
J Infect Dis. 2021 Jun 16;223(12 Suppl 2):S257-S263
pubmed: 33330904
Microb Cell Fact. 2020 Nov 7;19(1):203
pubmed: 33160356
Genome Biol. 2019 Nov 28;20(1):257
pubmed: 31779668
Hum Reprod. 2019 Jun 4;34(6):1042-1054
pubmed: 31119299
J Clin Microbiol. 2018 Nov 27;56(12):
pubmed: 30232133
Cell Res. 2020 Jun;30(6):492-506
pubmed: 32433595
Microb Pathog. 2019 Sep;134:103599
pubmed: 31212037
BJOG. 2020 Jan;127(2):208-216
pubmed: 31529767
Microbiol Resour Announc. 2021 Mar 4;10(9):
pubmed: 33664143
Genome Res. 2015 Dec;25(12):1910-20
pubmed: 26395152
Science. 2010 May 21;328(5981):994-9
pubmed: 20489017
Am J Obstet Gynecol. 2017 Sep;217(3):356.e1-356.e18
pubmed: 28549981
Nat Commun. 2019 Mar 21;10(1):1305
pubmed: 30899005
Am J Obstet Gynecol. 2018 Aug;219(2):189.e1-189.e12
pubmed: 29738749
Maturitas. 2016 Sep;91:42-50
pubmed: 27451320
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11060-5
pubmed: 26283357
Microbiome. 2013 Dec 02;1(1):29
pubmed: 24451163